IL87332A - Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them - Google Patents

Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them

Info

Publication number
IL87332A
IL87332A IL87332A IL8733288A IL87332A IL 87332 A IL87332 A IL 87332A IL 87332 A IL87332 A IL 87332A IL 8733288 A IL8733288 A IL 8733288A IL 87332 A IL87332 A IL 87332A
Authority
IL
Israel
Prior art keywords
variants
dna technology
trypsin inhibitor
pharmaceutical compositions
expression vector
Prior art date
Application number
IL87332A
Other languages
English (en)
Other versions
IL87332A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL87332A0 publication Critical patent/IL87332A0/xx
Publication of IL87332A publication Critical patent/IL87332A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL87332A 1987-08-07 1988-08-04 Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them IL87332A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8718777A GB2208511A (en) 1987-08-07 1987-08-07 Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology

Publications (2)

Publication Number Publication Date
IL87332A0 IL87332A0 (en) 1989-01-31
IL87332A true IL87332A (en) 1993-01-14

Family

ID=10621986

Family Applications (1)

Application Number Title Priority Date Filing Date
IL87332A IL87332A (en) 1987-08-07 1988-08-04 Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology, process, expression vector and recombinant host therefor and pharmaceutical compositions containing them

Country Status (11)

Country Link
US (2) US5118668A (xx)
EP (1) EP0307592B1 (xx)
JP (1) JP2894354B2 (xx)
KR (1) KR890003802A (xx)
AT (1) ATE173478T1 (xx)
AU (1) AU604953B2 (xx)
DE (1) DE3856265D1 (xx)
ES (1) ES2124685T3 (xx)
GB (1) GB2208511A (xx)
IL (1) IL87332A (xx)
ZA (1) ZA885764B (xx)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US5866413A (en) * 1989-03-06 1999-02-02 Board Of Regents Of The University Of Texas System Pai-1 mutants
ATE226636T1 (de) * 1989-03-06 2002-11-15 Univ Texas Serpin-resistenter t-pa; mutanten; gene
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
DE3930522A1 (de) * 1989-09-13 1991-03-21 Bayer Ag Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
US20030223977A1 (en) * 1991-03-01 2003-12-04 Ley Arthur Charles Kunitz domain mutants as cathepsin G inhibitors
ATE431364T1 (de) * 1991-03-01 2009-05-15 Dyax Corp Inhibitoren der menschlichen elastase von neutrophilen
JPH07509229A (ja) * 1992-07-13 1995-10-12 コルバス・インターナショナル、インコーポレイテッド ウシ膵トリプシン阻害因子から誘導される因子Ｘａの阻害因子
US5807980A (en) * 1992-07-13 1998-09-15 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor VIIa-tissue factor complex
US5650394A (en) * 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
WO1995018830A2 (en) * 1994-01-11 1995-07-13 Protein Engineering Corporation Inhibitors of human plasmin derived from the kunitz domains
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
EP1374469A1 (en) * 2001-03-27 2004-01-02 Aware, Inc. Receiver transparent q-mode
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
TR201900937T4 (tr) * 2002-08-28 2019-02-21 Dyax Corp Organların ve dokuların muhafaza edilmesine yönelik yöntem.
US9221867B2 (en) * 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
DK1587907T3 (da) * 2003-01-07 2011-04-04 Dyax Corp Kunitz-domænebibliotek
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060218667A1 (en) * 2004-10-12 2006-09-28 Vojdani Fakhrieh S Plant-produced recombinant aprotinin and aprotinin variants
US7741054B2 (en) * 2004-11-15 2010-06-22 Roche Diagnostics, Operations, Inc. High throughput prion assays
WO2006086870A1 (en) 2005-02-18 2006-08-24 Angiochem Inc. Aprotinin polypeptides for transporting a compound across the blood-brain barrier
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
GT200600180A (es) * 2005-04-29 2006-11-22 Proceso para preparar isatinas con control de formacion de subproductos
WO2007009229A1 (en) 2005-07-15 2007-01-25 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
CA2643693A1 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
US20090318534A1 (en) 2006-09-27 2009-12-24 The Regents Of The University Of California Methods and compositions for the treatment of skin diseases and disorders
WO2008110301A1 (de) * 2007-03-13 2008-09-18 Bayer Schering Pharma Aktiengesellschaft Aprotinin-varianten mit verbesserten eigenschaften
CN101815724B (zh) 2007-05-29 2015-02-25 安吉奥开米公司 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
KR101668803B1 (ko) * 2007-10-29 2016-10-24 헬릭스 바이오메딕스, 인코포레이티드 보호용 피부 관리 테트라펩티드
MX355683B (es) * 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CA2745524C (en) * 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8853353B2 (en) 2008-12-17 2014-10-07 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
EP3459564B1 (en) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
WO2011153642A1 (en) * 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
KR102169651B1 (ko) 2011-01-06 2020-10-23 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US10980892B2 (en) 2015-06-15 2021-04-20 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack
US20210177917A1 (en) 2017-08-31 2021-06-17 The Regents Of The University Of California Molecular bacteriotherapy to control skin enzymatic activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
JPH0616716B2 (ja) * 1986-10-14 1994-03-09 塩野義製薬株式会社 酵母におけるヒトｐｓｔｉの製造法
SE8604600L (sv) * 1986-10-29 1988-04-30 Nixflu Ab Anordning for att kontrollera kontokort
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
US5032573A (en) * 1987-03-23 1991-07-16 Bayer Aktiengesellschaft Homologs of aprotinin produced from a recombinant host, process, expression vector and recombinant host therefor and pharmaceutical use thereof
DE3724570A1 (de) * 1987-06-27 1989-01-05 Bayer Ag Human-aprotinin, dessen lys-rest in position 15 gegen einen anderen protogenen aminosaeurerest ausgetauscht ist
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
DE3930522A1 (de) * 1989-09-13 1991-03-21 Bayer Ag Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben

Also Published As

Publication number Publication date
GB2208511A (en) 1989-04-05
DE3856265D1 (de) 1998-12-24
US5770568A (en) 1998-06-23
ATE173478T1 (de) 1998-12-15
ZA885764B (en) 1989-04-26
JP2894354B2 (ja) 1999-05-24
JPH02480A (ja) 1990-01-05
AU2058888A (en) 1989-04-20
GB8718777D0 (en) 1987-09-16
AU604953B2 (en) 1991-01-03
EP0307592A2 (de) 1989-03-22
ES2124685T3 (es) 1999-02-16
IL87332A0 (en) 1989-01-31
US5118668A (en) 1992-06-02
EP0307592B1 (de) 1998-11-18
KR890003802A (ko) 1989-04-18
EP0307592A3 (de) 1990-06-06

Similar Documents

Publication Publication Date Title
IL87332A0 (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology,process,expression vector and recombinant host therefor and pharmaceutical compositions containing them
IL85020A0 (en) Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it
CA2005502A1 (en) Somatotropin analogs
PT81837A (en) Process for preparing oligopeptides and intermediates therefor
PT85977A (en) Process for the preparation of human apolipoprotein ai and their variant forms by recombinant dna methods
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
AU9026691A (en) New human recombinant gamma interferon
EP0330700A4 (en) Human prourokinase-like polypeptide.
AU3595489A (en) Amblyommin, a new active substance for anticoagulant therapy
HU9602894D0 (en) Non-splicing variants of gp350/220
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
ATE112290T1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
EP0290029A3 (en) (19-alanine) calcitonin

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees